Senzime
UPPSALA, SE / ACCESSWIRE / November 30, 2023 // Senzime (STO:SEZI) Senzime, an industry leader in algorithm-based patient monitoring solutions, today announced that it has secured multiple new orders for the TetraGraph system from several German university hospitals. The orders are the result of comprehensive clinical and competitive product evaluations. When fully deployed, these hospitals are expected to generate annual recurring revenue contributing significantly to announced financial targets.
"We continue to demonstrate that we are the trusted vendor of choice for leading hospitals that are starting to operate in the spirit of the new clinical guidelines of objective neuromuscular monitoring on patients receiving neuromuscular blocking drugs. Since our introduction on the German market in early 2021, our sales team has secured nearly 30 major hospital contracts including several key robotic surgery centers. These new orders are important milestones for us and indicators that the new European clinical guidelines are getting implemented in clinical practice", comments Philip Siberg, CEO of Senzime.
TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and that meets the new clinical guidelines published by ESAIC (European Society of Anaesthesiology and Intensive Care) and the ASA (American Society of Anesthesiologists).
The TetraGraph system is used during surgery to accurately monitor the patient's level of neuromuscular block. This helps anesthesiologists secure the right dose of neuromuscular blocking drugs and their antagonists during surgery, as well as indicate when it is safe to allow patients to breathe again on their own.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Attachments
Senzime secures multiple university hospital orders in Germany
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.SOURCE: Senzime
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
OmniGuide Holdings26.7.2024 14:07:40 CEST | Press release
OmniGuide Holdings Announces Successful Completion of Patient Study for Revolutionary iSTONE(TM) Laser-Guided Lithotripsy Technology
SpeedSize26.7.2024 12:31:59 CEST | Press release
SpeedSize Implements AI-Powered Media Optimization to Deliver Fast and Engaging Online Experience for Never Fully Dressed
Representing Animals Foundation25.7.2024 20:02:26 CEST | Press release
British Veterinary Association Ends Opposition to Vegan Diets for Dogs
U.S. Polo Assn.25.7.2024 13:02:58 CEST | Press release
U.S. Polo Assn. Serves as Official Apparel Partner for 2024 Cowdray Gold Cup
CGFNS International23.7.2024 18:23:16 CEST | Press release
CGFNS International Joins WHO Stakeholder Network to Advance Rehabilitation Care
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom